{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:53:30Z","timestamp":1782806010582,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12029-021-00711-0","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:02:30Z","timestamp":1632286950000},"page":"930-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Yoshinori","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-0723","authenticated-orcid":false,"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Seno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"711_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jjco\/hyn127","volume":"39","author":"T Shirasaka","year":"2009","unstructured":"Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39(1):2\u201315. https:\/\/doi.org\/10.1093\/jjco\/hyn127.","journal-title":"Jpn J Clin Oncol"},{"key":"711_CR3","doi-asserted-by":"publisher","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology G.\u00a0Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10 2009;(11):1063\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(09)70259-1.","DOI":"10.1016\/S1470-2045(09)70259-1"},{"issue":"3","key":"711_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncol"},{"issue":"9","key":"711_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547\u201353. https:\/\/doi.org\/10.1200\/JCO.2009.25.4706.","journal-title":"J Clin Oncol"},{"issue":"17","key":"711_CR6","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1016\/j.ejca.2013.07.003","volume":"49","author":"JA Ajani","year":"2013","unstructured":"Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin\/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin\/5-fluorouracil in the first-line advanced gastric cancer study. Eur J Cancer. 2013;49(17):3616\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2013.07.003.","journal-title":"Eur J Cancer"},{"issue":"1","key":"711_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdu472.","journal-title":"Ann Oncol"},{"issue":"3","key":"711_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10120-015-0518-8","volume":"19","author":"S Matsusaka","year":"2016","unstructured":"Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2016;19(3):839\u201351. https:\/\/doi.org\/10.1007\/s10120-015-0518-8.","journal-title":"Gastric Cancer"},{"issue":"1","key":"711_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186.","journal-title":"N Engl J Med"},{"issue":"9742","key":"711_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"5","key":"711_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00280-016-3013-y","volume":"77","author":"H Kataoka","year":"2016","unstructured":"Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, Hirata Y, Sobue S, Mizushima T, Sano H, Mizuno Y, Nakamura M, Hirano A, Tsuchida K, Adachi K, Seno K, Kitagawa M, Kawai T, Joh T. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. Cancer Chemother Pharmacol. 2016;77(5):957\u201362. https:\/\/doi.org\/10.1007\/s00280-016-3013-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"711_CR12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10120-019-00973-5","volume":"22","author":"D Takahari","year":"2019","unstructured":"Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, Nishina T, Nakajima TE, Amagai K, Machida N, Goto M, Taku K, Wakatsuki T, Shoji H, Hironaka S, Boku N, Yamaguchi K. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238\u201346. https:\/\/doi.org\/10.1007\/s10120-019-00973-5.","journal-title":"Gastric Cancer"},{"issue":"1","key":"711_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-019-03991-3","volume":"85","author":"S Yuki","year":"2020","unstructured":"Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC\/HGCSG\/CCOG\/PerSeUS 1501B. Cancer Chemother Pharmacol. 2020;85(1):217\u201323. https:\/\/doi.org\/10.1007\/s00280-019-03991-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"711_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"711_CR15","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.7314\/apjcp.2015.16.13.5433","volume":"16","author":"S Kadowaki","year":"2015","unstructured":"Kadowaki S, Komori A, Takahari D, Ura T, Ito S, Tajika M, Niwa Y, Oze I, Muro K. Clinical characteristics associated with long-term survival in metastatic gastric cancer after systemic chemotherapy. Asian Pac J Cancer Prev. 2015;16(13):5433\u20138. https:\/\/doi.org\/10.7314\/apjcp.2015.16.13.5433.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"711_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bjc.2014.18","volume":"110","author":"Y Kurokawa","year":"2014","unstructured":"Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110(5):1163\u20138. https:\/\/doi.org\/10.1038\/bjc.2014.18.","journal-title":"Br J Cancer"},{"issue":"4","key":"711_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ejca.2014.12.015","volume":"51","author":"MH Ryu","year":"2015","unstructured":"Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51(4):482\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2014.12.015.","journal-title":"Eur J Cancer"},{"key":"711_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12885-016-2092-9","volume":"16","author":"J Gong","year":"2016","unstructured":"Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, Liu W, Wang L, Shen L. Optimal regimen of trastuzumab in combination with oxaliplatin\/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68. https:\/\/doi.org\/10.1186\/s12885-016-2092-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"711_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00280-019-03820-7","volume":"83","author":"F Rivera","year":"2019","unstructured":"Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martinez E, Jorge M, Arrazubi V, Mendez JC, Garcia-Alfonso P, Reboredo M, Barriuso J, Munoz-Unceta N, Jimeno R, Lopez C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019;83(6):1175\u201381. https:\/\/doi.org\/10.1007\/s00280-019-03820-7.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-021-00711-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:19:21Z","timestamp":1667416761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-021-00711-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s12029-021-00711-0","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"8 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent before enrollment. This study was approved by Institutional Review Board of all hospitals and registered with UMIN-CTR (UMIN000017182).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All the authors have read the manuscript and have approved participation, this submission and publication in <i>Journal of Gastrointestinal Cancer<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}